scispace - formally typeset
J

Jasna Klicic

Researcher at Columbia University

Publications -  11
Citations -  7383

Jasna Klicic is an academic researcher from Columbia University. The author has contributed to research in topics: Cancer & Transplantation. The author has an hindex of 6, co-authored 11 publications receiving 6324 citations. Previous affiliations of Jasna Klicic include Merck Serono & D. E. Shaw Research.

Papers
More filters
Journal ArticleDOI

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

TL;DR: Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand to find the best docked pose using a model energy function that combines empirical and force-field-based terms.
Journal ArticleDOI

Accurate Prediction of Acidity Constants in Aqueous Solution via Density Functional Theory and Self-Consistent Reaction Field Methods

TL;DR: In this article, the acidity constant (pKa) of organic compounds is computed via ab initio quantum chemistry and continuum solvation methods. But the intrinsic accuracy of these approaches is quite impressive (errors on the order of a few kcal/mol), it is not quite good enough to achieve the target accuracy that we have set for pKa prediction of 0.5 pKa units.
Journal ArticleDOI

Furan-2-ylmethylene Thiazolidinediones as Novel, Potent, and Selective Inhibitors of Phosphoinositide 3-Kinase γ

TL;DR: A novel series of furan-2-ylmethylene thiazolidinediones as selective, ATP-competitive PI3Kgamma inhibitors are disclosed and Compound 26 (AS-252424), a potent and selective small-molecule PI3kgamma inhibitor emerging from these efforts, was further profiled in three different cellular PI 3K assays and shown to be selective for class IB PI2K-mediated cellular effects.
Patent

Pyrazine derivatives and use as pi3k inhibitors

TL;DR: In this paper, a pyrazine derivatives of Formula (I) were used for the treatment and/or prophylaxis of autoimmune disorders and inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
Journal ArticleDOI

1,3-Dipolar Addition of Phenylazide to the Carbon−Carbon Double Bond: An ab Initio Study

TL;DR: In this paper, the activation energy of the 1,3-dipolar addition of phenylazide to 19 different reactants containing a carbon−carbon double bond was calculated using density functional methods and large basis sets.